Adrienne Scott, MD
Ophthalmology · Baltimore, MDNPI 1174537534
Payments from drug & device makers
Across 194 payments — averaging $1612.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$130K
- AbbVie$34K
- Regeneron$34K
- Genentech USA, Inc.$28K
- Novartis$18K
- Astellas Pharma US Inc$16K
- plus $52K from 17 others
Across 17 payments — averaging $1253.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$21K
What the payments were for
- Consulting fees$144,30385%
- Speaking & faculty fees$13,6638%
- Travel & lodging$6,8964%
- Food & beverage$4,8973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 27 | $130,157 |
| AbbVie(2 entities) | 41 | $34,350 |
| Regeneron | 20 | $33,631 |
| Genentech USA, Inc. | 23 | $28,268 |
| Novartis | 7 | $18,361 |
| Astellas Pharma US Inc | 6 | $16,499 |
| Alcon | 15 | $15,415 |
| Regeneron Healthcare Solutions, Inc. | 13 | $12,580 |
| Apellis Pharmaceuticals, Inc. | 16 | $9,075 |
| Eyepoint US, Inc. | 8 | $4,481 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $3,896 |
| Dutch Ophthalmic, USA | 2 | $2,643 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $1,500 |
| Alimera Sciences, Inc. | 2 | $1,315 |
| Astellas Pharma Global Development | 2 | $205 |
| Ocular Therapeutix, Inc. | 1 | $111 |
| Biogen | 1 | $84 |
| Amgen | 1 | $79 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Harrow Eye, LLC | 1 | $52 |
| Carl Zeiss Meditec USA, Inc. | 1 | $45 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Coopervision Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$27,855
- EYLEA$25,413
- Izervay$16,518
- Unity$15,001
- Constellation$14,861
- VABYSMO$14,568
- ADAKVEO$10,750
- Lucentis$8,580
- BEOVU$6,450
- EYLEA HD$4,173
- Syfovre$3,477
- EYP-1901$2,678
- EVA, combined machine$2,625
- YUTIQ$1,850
- XIPERE$1,500
- Iluvien$1,315
- NGENUITY$1,148
- FINESSE SHARKSKIN$1,003
- SUSVIMO$959
- Alcon Greishaber Finesse$392
How this compares
$312,868 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 35 | $1,186 |
| Ketorolac Tromethamine | 33 | $922 |
| ErythromycinErythromycin Base | 24 | $181 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Baltimore
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- John ThompsonBaltimore$1.8M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$1.1M
- Earl CravenBaltimore$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.